K C Birendra1, Courtney D DiNardo2. 1. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 2. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: cdinardo@mdanderson.org.
Abstract
BACKGROUND: Cancer-associated isocitrate dehydrogenase (IDH) mutations block normal cellular differentiation via production of the oncometabolite, R-2-hydroxyglutarate. In patients with acute myeloid leukemia (AML) receiving targeted mutant IDH inhibitor therapy, neutrophil recovery within the setting of clinical differentiation syndrome (DS) has been anecdotally described. PATIENTS AND METHODS: We describe 3 patients who developed clinically apparent DS during monotherapy with the mutant IDH1 inhibitor, AG-120, for relapsed/refractory AML. RESULTS: AG-120-induced differentiation commenced within the first 60 days of treatment, notably in the same time frame as clinical response, strengthening the purported mechanism of targeted mutant IDH inhibitor therapy via successful myeloid maturation. Symptoms of DS were nonspecific and included culture-negative fever, edema, hypotension, malaise, and pleural and/or pericardial effusions, in addition to marked neutrophil-predominant leukocytosis. CONCLUSION: DS can occur during treatment with targeted mutant IDH1 inhibitor therapy. Patients might present with nonspecific clinical manifestations often in the setting of leukocytosis related to exuberant neutrophil recovery. Prompt identification and initiation of treatment interventions, including hydroxyurea, corticosteroids, and/or consideration of temporary treatment discontinuation, are important to facilitate prompt resolution.
BACKGROUND: Cancer-associated isocitrate dehydrogenase (IDH) mutations block normal cellular differentiation via production of the oncometabolite, R-2-hydroxyglutarate. In patients with acute myeloid leukemia (AML) receiving targeted mutant IDH inhibitor therapy, neutrophil recovery within the setting of clinical differentiation syndrome (DS) has been anecdotally described. PATIENTS AND METHODS: We describe 3 patients who developed clinically apparent DS during monotherapy with the mutant IDH1 inhibitor, AG-120, for relapsed/refractory AML. RESULTS:AG-120-induced differentiation commenced within the first 60 days of treatment, notably in the same time frame as clinical response, strengthening the purported mechanism of targeted mutant IDH inhibitor therapy via successful myeloid maturation. Symptoms of DS were nonspecific and included culture-negative fever, edema, hypotension, malaise, and pleural and/or pericardial effusions, in addition to marked neutrophil-predominant leukocytosis. CONCLUSION:DS can occur during treatment with targeted mutant IDH1 inhibitor therapy. Patients might present with nonspecific clinical manifestations often in the setting of leukocytosis related to exuberant neutrophil recovery. Prompt identification and initiation of treatment interventions, including hydroxyurea, corticosteroids, and/or consideration of temporary treatment discontinuation, are important to facilitate prompt resolution.
Authors: M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; J M Rowe; C François; R S Larson; P H Wiernik Journal: Blood Date: 2000-01-01 Impact factor: 22.113
Authors: S R Frankel; A Eardley; G Heller; E Berman; W H Miller; E Dmitrovsky; R P Warrell Journal: Ann Intern Med Date: 1994-02-15 Impact factor: 25.391
Authors: Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su Journal: Nature Date: 2009-12-10 Impact factor: 49.962
Authors: Maaike Luesink; Jeroen L A Pennings; Willemijn M Wissink; Peter C M Linssen; Petra Muus; Rolph Pfundt; Theo J M de Witte; Bert A van der Reijden; Joop H Jansen Journal: Blood Date: 2009-10-14 Impact factor: 22.113
Authors: S De Botton; H Dombret; M Sanz; J S Miguel; D Caillot; R Zittoun; M Gardembas; A Stamatoulas; E Condé; A Guerci; C Gardin; K Geiser; D C Makhoul; O Reman; J de la Serna; F Lefrere; C Chomienne; C Chastang; L Degos; P Fenaux Journal: Blood Date: 1998-10-15 Impact factor: 22.113
Authors: Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson Journal: Cancer Cell Date: 2010-02-18 Impact factor: 38.585
Authors: Hyun Don Yun; Sunita Nathan; Melissa Larson; Mohammad J Hussain; Deborah A Katz; Ankur Varma; Ira Miller; Celalettin Ustun Journal: Blood Adv Date: 2019-11-26
Authors: Cheyennedra C Bieg-Bourne; Sherri Z Millis; David E Piccioni; Paul T Fanta; Michael E Goldberg; Juliann Chmielecki; Barbara A Parker; Razelle Kurzrock Journal: Cancer Res Date: 2017-09-22 Impact factor: 12.701